摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4,8-diamino-1-benzyl-6H-6-iminoimidazo<4,5-e><1,3>diazepine | 162009-80-5

中文名称
——
中文别名
——
英文名称
4,8-diamino-1-benzyl-6H-6-iminoimidazo<4,5-e><1,3>diazepine
英文别名
1-benzyl-4,8-diamino-6-imino-1,6-dihydroimidazo[4,5-e][1,3]diazepine;4,8-diamino-1-benzyl-6-iminoimidazo[4,5-e][1,3]diazepine;3-Benzyl-6-iminoimidazo[4,5-e][1,3]diazepine-4,8-diamine
4,8-diamino-1-benzyl-6H-6-iminoimidazo<4,5-e><1,3>diazepine化学式
CAS
162009-80-5
化学式
C13H13N7
mdl
——
分子量
267.293
InChiKey
XVYUFUDNPUPIDU-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.1
  • 重原子数:
    20
  • 可旋转键数:
    2
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.08
  • 拓扑面积:
    118
  • 氢给体数:
    3
  • 氢受体数:
    2

反应信息

  • 作为反应物:
    参考文献:
    名称:
    A Short Synthesis of a Novel Ring-Expanded Purine and Its Nucleoside Analogue Containing the Imidazo[4,5-e][1,3]diazepine Ring Skeleton with Multiple Amino Substituents Attached to the 7-Membered Ring
    摘要:
    The synthesis of 4,6,8-triaminoimidazo[4,5-e][1,3]diazepine (1) and its nucleoside analogue (6) are reported. The heterocycle was prepared in a single step by condensation of 4,5-dicyanoimidazole with guanidine. The 5,7-fused ring structure of 1 was distinguished from the other possible 5:5-fused isomer 2 by preparing the N-15-labeled heterocycle (1*) and exploring its N-15-H-1 coupling patterns in both H-1 and N-15 NMR spectra. These spectral patterns also enabled establishment of the triamino tautomeric form of 1 as assigned. Compound 1, a novel ring-expanded (''fat'') analogue of purine, is anticipated to be planar and aromatic as predicted by molecular modeling. The 1-benzyl analogue (4), a protocol for the ribosyl analogue 6, was similarly prepared from 1-benzyl-4,5-dicyanoimidazole. The nucleoside 6 was prepared by the modified Vorbruggen ribosylation of 1. The position of ribosylation was unequivocally established by an unambiguous synthesis of 6 from condensation of 1-(2',3',5'-tri-O-benzoyl-beta-($) under bar D-ribofuranosyl)-4,5-dicyanoimidazole (7) with guanidine in a solution of sodium methoxide in methanol. The nucleoside 7 was prepared by the Vorbruggen ribosylation of 4,5-dicyanoimidazole.
    DOI:
    10.1080/15257779408013222
  • 作为产物:
    参考文献:
    名称:
    含有5:7稠合的4,6,8-三氨基咪唑并[4,5- e ] [1,3]二氮杂ring环系统的化合物的合成,抗癌活性和SAR分析
    摘要:
    本文描述的是我们对5:7稠合杂环(1)的有限结构-活性关系(SAR)研究,该杂环包含4,6,8-三氨基咪唑并[4,5- e ] [1,3]二氮杂pine环系统,我们在几年前报道了其合成和有效的广谱抗癌活性。我们在这项研究中的SAR努力主要集中在杂环的N-1和N 6位上取代基的合法连接上。我们的结果表明,在杂环的N-1位上连接的取代基与在杂环的N 6位上连接的取代基之间存在一些微妙的相关性。在靶蛋白上可能有一个常见的疏水结合口袋,被N-1和N 6处的取代基所占据杂环配体的-位。该口袋似乎足够大,可以容纳N 6的C-18烷基链,而在N-1处没有任何连接,或者在N 6处具有结合的C-10,在N-1处具有CH 2 Ph。在N 6处短于或长于C-10且在N-1处连接有CH 2 Ph的任何烷基链会导致生物活性降低。
    DOI:
    10.1016/j.bmc.2016.03.015
点击查看最新优质反应信息

文献信息

  • Ring expanded nucleosides and nucleotides
    申请人:——
    公开号:US20040077564A1
    公开(公告)日:2004-04-22
    The present invention relates to compositions comprising analogues of purine nucleosides containing a ring-expanded (“fat”) heterocyclic ring, in place of purine, and an unmodified or modified sugar residue, pharmaceutically acceptable derivatives of such compositions, as well as methods of use thereof. In particular, these compositions may be utilized in the treatment of certain cancers, bacterial, fungal, parasitic, and viral infections, including, but not limited to, Acquired Immunodeficiency Syndrome (AIDS), hepatitis, Epstein-Barr and cytomegalovirus.
    本发明涉及含有环扩张(“肥胖”)杂环环代替嘌呤的嘌呤核苷类似物和未经改性或改性的糖残基的组合物,以及这些组合物的药学上可接受的衍生物,以及其使用方法。特别地,这些组合物可用于治疗某些癌症、细菌、真菌、寄生虫和病毒感染,包括但不限于获得性免疫缺陷综合症(AIDS)、肝炎、EB病毒和巨细胞病毒。
  • Ring-expanded nucleosides and nucleotides
    申请人:Nabi
    公开号:EP1227103B1
    公开(公告)日:2006-07-26
  • RING-EXPANDED NUCLEOSIDES AND NUCLEOTIDES
    申请人:Nabi
    公开号:EP0724587B1
    公开(公告)日:2002-09-04
  • US6677310B1
    申请人:——
    公开号:US6677310B1
    公开(公告)日:2004-01-13
  • A Short Synthesis of a Novel Ring-Expanded Purine and Its Nucleoside Analogue Containing the Imidazo[4,5-<i>e</i>][1,3]diazepine Ring Skeleton with Multiple Amino Substituents Attached to the 7-Membered Ring
    作者:L. Wang、A. Bhan、R. S. Hosmane、R. D. Guiles
    DOI:10.1080/15257779408013222
    日期:1994.12
    The synthesis of 4,6,8-triaminoimidazo[4,5-e][1,3]diazepine (1) and its nucleoside analogue (6) are reported. The heterocycle was prepared in a single step by condensation of 4,5-dicyanoimidazole with guanidine. The 5,7-fused ring structure of 1 was distinguished from the other possible 5:5-fused isomer 2 by preparing the N-15-labeled heterocycle (1*) and exploring its N-15-H-1 coupling patterns in both H-1 and N-15 NMR spectra. These spectral patterns also enabled establishment of the triamino tautomeric form of 1 as assigned. Compound 1, a novel ring-expanded (''fat'') analogue of purine, is anticipated to be planar and aromatic as predicted by molecular modeling. The 1-benzyl analogue (4), a protocol for the ribosyl analogue 6, was similarly prepared from 1-benzyl-4,5-dicyanoimidazole. The nucleoside 6 was prepared by the modified Vorbruggen ribosylation of 1. The position of ribosylation was unequivocally established by an unambiguous synthesis of 6 from condensation of 1-(2',3',5'-tri-O-benzoyl-beta-($) under bar D-ribofuranosyl)-4,5-dicyanoimidazole (7) with guanidine in a solution of sodium methoxide in methanol. The nucleoside 7 was prepared by the Vorbruggen ribosylation of 4,5-dicyanoimidazole.
查看更多

同类化合物

脱氧助间型霉素 化合物RK-33 8-叔-丁基1-乙基6,7-二氢-5H-咪唑并[1,5-A][1,4]二氮杂卓-1,8(9H)-二甲酸基酯 8-(叔丁氧羰基)-6,7,8,9-四氢-5H-咪唑并[1,5-A][1,4]二氮杂-1-羧酸 6-羟基-4,5,6,7-四氢咪唑并[4,5-e][1,4]二氮杂卓-8(1H)-酮 5-(8-羟基-7,8-二氢-4H-咪唑并[5,4-d][1,3]二氮杂卓-3-基)-3-(羟基甲基)环戊-3-烯-1,2-二醇 4,7-二氢咪唑并[4,5-d][1,3]二氮杂卓-8(1H)-酮 3-[(2-羟基乙氧基)甲基]-3,4,7,8-四氢咪唑并[4,5-d][1,3]二氮杂卓-8-醇 1H-咪唑并[1,5-d〕〔1,4]二氮杂(9CI) 1,4,6,7-四氢咪唑并[4,5-e][1,4]二氮杂卓-5,8-二酮 (9ci)-1H-咪唑并[1,2-a][1,4]二氮杂卓 5-methylthio-11H-imidazo[1,2-c][1,3]benzodiazepine 2-methoxy-1,4,7-trimethyl-4,5,7,8-tetrahydro-6H-imidazo<4,5-e><1,4>diazepine-5,8-dione 1-benzyl-5,7-diphenyl-4,5,7,8-tetrahydroimidazo<4,5-e><1,3>diazepin-6-one 6-amino-4,5-dihydro-8H-imidazo[4,5-e][1,3]diazepine-4,8-dione [3-(2-Deoxy-β-D-erythro-pentofuranosyl)-3,6,7,8 tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol]-5'-phosphoric Acid-(3-dodecylmercapto-2-decyloxy)-propyl Ester (4S)-4-benzyl-2-(2,5-dihydroxyphenyl)-3,4-dihydro-5H-pyrido[1',2':1,2]imidazo-[4,5-d][1,3]diazepin-5-one (4S)-4-benzyl-2-(2,5-dimethoxyphenyl)-3,4-dihydro-5H-pyrido[10,20:1,2]imidazo [4,5-d][1,3]diazepin-5-one (4S)-4-methyl-2-(1-naphthyl)-3,4-dihydro-5H-pyrido[1',2':1,2]imidazo-[4,5-d][1,3]diazepin-5-one 6-amino-1-(2'-deoxy-β-D-erythropentofuranosyl)-4,5-dihydro-8H-imidazo[4,5-e][1,3]diazepine-4,8-dione 6-amino-1-(2'-deoxy-α-D-erythropentofuranosyl)-4,5-dihydro-8H-imidazo[4,5-e][1,3]diazepine-4,8-dione (4S)-4-methyl-2-(4-acetamidophenyl)-3,4-dihydro-5H-pyrido[1',2':1,2]imidazo-[4,5-d][1,3]diazepin-5-one 5-(4-methyl-1-piperazinyl)-11H-imidazo[1,2-c][1,3]benzodiazepine monomaleate (8R)-3-[(4R,5S)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7,8-dihydro-4H-imidazo[4,5-d][1,3]diazepin-8-ol (R)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol 6-(decylamino)-1-[(2S,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7H-imidazo[4,5-e][1,3]diazepine-4,8-dione (13S)-11-(4-methoxyphenyl)-13-methyl-2,8,10,12-tetrazatricyclo[7.5.0.02,7]tetradeca-1(9),3,5,7,11-pentaen-14-one (8R)-3-[(2S,4S,5S)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7,8-dihydro-4H-imidazo[4,5-d][1,3]diazepin-8-ol 8-Ketodeoxycoformycin 2'-chloropentostatin CO-Vidarabine (8R)-3-[(1S,2R,4R)-2-(benzoyloxymethyl)-1-benzoyloxycyclopent-4-yl]-8-[(tert-butyldimethylsilyl)oxy]-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepine (8R)-3-Benzyl-6-(tert-butoxycarbonyl)-8-<(tert-butyldimethylsilyl)oxy>-3,6,7,8-tetrahydroimidazo<4,5-d><1,3>diazepine (8R)-3-(2'-Cyanoethyl)-8-<(tert-butyldimethylsilyl)oxy>-3,6,7,8-tetrahydroimidazo<4,5-d><1,3>diazepine 4-propyl-4,5,7,8-tetrahydro-6H-imidazo<4,5-e><1,4>diazepine-5,8-dione 1-benzyl-4-propyl-4,5,7,8-tetrahydro-6H-imidazo<4,5-e><1,4>diazepine-5,8-dione 4-isobutyl-7-methyl-4,5,7,8-tetrahydro-6H-imidazo<4,5-e><1,4>diazepine-5,8-dione 1-benzyl-4,7-diethyl-4,5,7,8-tetrahydro-6H-imidazo<4,5-e><1,4>diazepine-5,8-dione 1-benzyl-4-isobutyl-7-methyl-4,5,7,8-tetrahydro-6H-imidazo<4,5-e><1,4>diazepine-5,8-dione 4,6-diamino-6-(ethylimino)-1,6-dihydroimidazo[4,5-e][1,3]diazepine 4,5-dihydro-8H-6-(N-hexadecyl)amino-1-(2'-deoxy-α-D-erythropentofuranosyl)imidazo[4,5-e]diazepine-4,8-dione 4,5-dihydro-8H-6-(N-tetradecyl)amino-1-(2'-deoxy-α-D-erythropentofuranosyl)imidazo[4,5-e]diazepine-4,8-dione 4,5-dihydro-8H-6-(N-octadecyl)amino-1-(2-deoxy-α-D-erythropentofuranosyl)imidazo[4,5-e]diazepine-4,8-dione 4,6-diamino-6-(octadecylimino)-1,6-dihydroimidazo[4,5-e][1,3]diazepine 8-Imino-2,4-dimethyl-7-phenyl-7,8-dihydro-4H-1,2a,4,5,7-pentaaza-cyclopenta[cd]azulene-3,6-dione 1,4-dimethyl-4,5,7,8-tetrahydro-6H-imidazo<4,5-e><1,4>diazepine-5,8-dione 11H-imidazo[1,2-c][1,3]benzodiazepine-5(6H)-thione (8R)-3-[(4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7,8-dihydro-4H-imidazo[4,5-d][1,3]diazepin-8-ol 2-(4-Chloro-benzylcarbamoyl)-6-(8-hydroxy-7,8-dihydro-6H-imidazo[4,5-d][1,3]diazepin-3-yl)-hexanoic acid benzyl ester (13S)-13-(1H-indol-3-ylmethyl)-2,8,10,12-tetrazatricyclo[7.5.0.02,7]tetradeca-1(9),3,5,7-tetraene-11,14-dione